Physician profile
Ani Berberyan
NPI 1700230224
$1,478.97
in general payments reported to CMS, 2019-2025
22 companies · $14.68 in 2025
The $14.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $286 · 2021: $590 · 2022: $208 · 2023: $65.23 · 2024: $159 · 2025: $14.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $161.79 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $146.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $140.94 | 2021-2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.46 | 2021-2022 | |
| Abbvie INC. | $129.59 | 2021 | |
| Allergan, INC. | $78.82 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $77.60 | 2020-2021 | |
| Glaxosmithkline, LLC. | $73.10 | 2020-2025 | Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $70.23 | 2022 | |
| Pfizer INC. | $66.44 | 2020-2023 | |
| Lilly USA, LLC | $65.31 | 2020-2021 | |
| Astellas Pharma US INC | $55.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $53.64 | 2021 | |
| Novo Nordisk INC | $43.99 | 2021-2023 | |
| Amgen INC. | $42.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.11 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.41 | 2023 | Gvoke Hypopen |
| Aurinia Pharma U.S., INC. | $23.33 | 2024 | Lupkynis |
| Eisai INC. | $16.18 | 2020 | |
| Bard Peripheral Vascular, INC. | $12.55 | 2021 | |
| Ibsa Pharma INC. | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ani Berberyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.